Novartis released new data for Lucentis in a series of abstracts at the EURETINA congress. Based on meta-analysis of 14 trials and 6504 patients, Lucentis sustained its safety profile. Lucentis is indicated in many countries for the treatment of wet age-related macular degeneration (wet AMD), for visual impairment due to diabetic macular edema (DME), macular edema secondary to branch- and central-retinal vein occlusion (BRVO and CRVO), and choroidal neovascularization secondary to pathologic myo...